Dr. Gordon J. Vanscoy, Chairman & CEO of PANTHERx Rare & RareMed Solutions, Named an EY Entrepreneur Of The Year® 2020 National Award Winner
Read the Official PANTHERx Press Release. Ernst & Young LLP (EY US) yesterday announced that Dr. Gordon J. Vanscoy, Chairman & CEO of both PANTHERx Rare and RareMed Solutions, was named an Entrepreneur Of The Year® 2020 National Award winner following...
Read More
PANTHERx® Rare Pharmacy Selected by Blueprint Medicines to Distribute GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Blueprint Medicines as a limited distribution partner for new drug GAVRETO™ (pralsetinib), which was granted -accelerated approval for the treatment...
Read More
PANTHERx® Rare Pharmacy Selected by Ultragenyx Pharmaceutical to Distribute DOJOLVI™ (triheptanoin), for Patients with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Ultragenyx Pharmaceutical as a limited distribution partner for new drug DOJOLVITM (triheptanoin). DOJOLVI™ (a highly purified, pharmaceutical-grade,...
Read More
PANTHERx® Chosen as Exclusive Rare Pharmacy Partner by Viela Bio, Inc. for Uplizna™ (inebilizumab-cdon) for Adult Patients with AQP4+ Neuromyelitis Optica Spectrum Disorder (NMOSD)
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Viela Bio, Inc. as their sole rare pharmacy partner for new drug Uplizna™ (inebilizumab-cdon). The drug has been approved for the treatment of neuromyelitis...
Read More
PANTHERx Rare Pharmacy Recognized as a US Best Managed Company
Read the Official PANTHERx Press Release. PANTHERx Rare Pharmacy (PANTHERx), was officially recognized as a prestigious US Best Managed Company for overall business performance and sustained growth. The US Best Managed Company designation, sponsored by...
Read More
PANTHERx® Rare Pharmacy Selected by Deciphera Pharmaceuticals to Distribute QINLOCK™ (ripretinib), for Gastrointestinal Stromal Tumor (GIST) Patients
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Deciphera Pharmaceuticals as a limited distribution partner for new drug QINLOCKTM (ripretinib). QINLOCK™ is a kinase inhibitor indicated for the...
Read More